Navigation Links
Callisto Intends to Move Guanilib into Clinical Trials in,Ulcerative Colitis

Announces Positive Data in Animal Models of Ulcerative Colitis

NEW YORK, April 05, 2007 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. , a developer of new drug treatments in the fight against cancer and other major health threats, announced today additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis. Guanilib is an orally deliverable compound designed to mimic a naturally-occurring hormone called uroguanylin. The drug is currently in preclinical development and Callisto intends to move the drug into clinical trials in ulcerative colitis. Guanilib is a proprietary program that was developed in-house by Callisto scientists and the company owns 100% of the worldwide manufacturing and marketing rights.

The new animal data demonstrate that oral administration of Guanilib significantly reduces gastrointestinal (GI) inflammation, and confirm earlier evidence of down-regulation of interleukin-17 (IL-17), IL-23, and tumor necrosis factor (TNF), key cytokines that are known to be involved in etiology of IBD in humans. Guanilib treatment also improved stool consistency and removed intestinal blockage in treated animals.

"These are important findings and suggest a possible mechanism of action of Guanilib and implicate its therapeutic potential in GI inflammatory diseases such as IBD and IBS," said Dr. Kunwar Shailubhai, Senior Vice President, Discovery Research of Callisto, who is also the lead inventor of the issued patent covering therapeutic applications of Guanilib in GI inflammatory diseases and colon cancer.

Callisto believes that Guanilib is presently the best physiological ligand of guanylate cyclase receptor with the potential to provide a new way to treat gastrointestinal diseases, while exhibiting minimal side effects
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:12/1/2008)...ORE, Dec. 1 S*BIO Pte Ltd today an...al of SB1518, a potent and orally-active JAK2 inhi... patients with chronic idiopathic myelofibrosis (C...e the safety and tolerability of SB1518 in patient...ents. The Phase 1 part of the study will assess t...
(Date:12/1/2008)...TH MEETING, Pa., Dec. 1 ...nced that dosing of subjects has begun in study MS...se Phase 1b study of trodusquemine (MSI-1436) in o...a novel therapeutic for the treatment of type 2 di...herally to regulate insulin and leptin pathways th...
(Date:11/30/2008)... , CHICAGO, Dec. 1 O...cerebral blood flow and a greater number of small ...presented today at the annual meeting of the Radio... The study, conducted at the University of Nort... compare brain scans of older adults who exercise ...
(Date:11/26/2008)...TER, Minn., Nov. 26 Chi...are at significantly increased risk of developing ...ndings of a Mayo Clinic study published this mont...ican Academy of Pediatrics. , , The retrosp...atients with strabismus (misaligned eyes) and comp...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Eye Divergence in Children Triples Risk of Mental Illness 2Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 1Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 2Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 3Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 4Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 5Wyeth Initiates INTORACT A New Clinical Trial to Examine TORISEL Plus Avastin for First Line Treatment of Advanced Kidney Cancer 2244 6Tumor suppressor genes speed up and slow down aging in engineered mouse 20708 1Nations Only Health Museum Makes You Sole Focus of New Exhibit Gallery 20705 1Nations Only Health Museum Makes You Sole Focus of New Exhibit Gallery 20705 2Nations Only Health Museum Makes You Sole Focus of New Exhibit Gallery 20705 3Bio Pharma Industry Experts Deliver M 26A Value Through Integration Excellence 5711 1Bio Pharma Industry Experts Deliver M 26A Value Through Integration Excellence 5711 2
...P-1 in Neuropathic Pain, TARRYTOWN, N.Y., May 03, ... announced today that it will present new data for...26th Annual,Scientific Meeting of the American Pai...ented topical cream formulation of two,FDA-approve... a,product candidate intended for use in the manag...
...nal Conference on Antiviral,Research, SAN DIEGO, M...rmaceuticals, Inc. , a biopharmaceutical research ... proprietary product,candidates for the treatment ... that it presented results demonstrating synergist...d flu) viruses when,the Company,s broad-spectrum a...
Other Medicine Technology:EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 2EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 3EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 4EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting 5ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 2ANX-201 Drug Combination Demonstrates Synergistic Activity Against,Human and Bird Flu Viruses 3
(Date:12/2/2008)... NDA with FDA in Early to Mid-2009 , , WARR...velopers of PharmFilm(R) technology and a drug del... pharmaceutical products, and Strativa Pharmaceuti...rmaceutical Companies, Inc. (NYSE: PRX ), today ... bioequivalence studies for a thin film formulatio...
(Date:12/2/2008)...c. 2 With the bright lights, sweet...holidays may be an exciting time of year for any c..., especially with today,s tough economy. Whether ...ptying their wallets, or spending hours traveling ...elax, and even less time to be alone and romantic ...
(Date:12/2/2008)...Dec. 2 Aduromed Industri...ovider of medical waste treatment,systems, today ... on November,24, 2008 to protect the Company,s pr...nerized MedClean Systems that provide a turnkey so...zation and volume reduction. , The patent a...
(Date:12/2/2008).... 2 Mylan Inc. (NYSE: ... Mylan Pharmaceuticals Inc., have entered,into a ... Corp., Novartis,Corp. and Novartis International...sion of Novartis, Femara(R). , Mylan,s Vice...re very,pleased to have reached this agreement, w...
Breaking Medicine News(10 mins):Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 2Health News:Jennie Finch Shares how to Fire up the Romance Despite the Demands of the Holidays 3Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 2Health News:Aduromed Files Patent Application to Cover Proprietary New Standard for Containerized, Turnkey Solution 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2
... the risk of diabetes in the Indigenous population...ott, Pro-vice Chancellor of the Division of Health...ows that while clinical care of adults with diabet...ndigenous Australians are developing the disease. ...
... epidemic of diabetes in the US is out. Spending o.... According to a drug trend report released by th...ailed only cholesterol medications in total prescr...n 2006. An aging population and the alarming rise...
...disfiguring accident that nearly killed him, but h...s home on Andrews Air Force Base in Maryland. N...e, that is, because of his brand-new nose. In a s... over a year-long period that ended with removal o...
...al Boston) and colleagues have identified the canc... soft-tissue sarcoma of childhood. 'Identifying ...ved genetic programs underlying self-renewal in ER... into how to destroy these cell types in establish...
Other Medicine News:Health News:Spending on Diabetes Drugs Soars in US 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 2Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 3Health News:Surgeons Perform Nasal Reconstruction for War Veteran Using His Own Body Parts 4Health News:Pediatric Cancer Stem Cell Identified 2
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)
Used for stone manipulation and removal in the urinary tract. Supplied sterile in peel-open packages. Intended for one-time use.
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
BARDEX Red Rubber Urethral Catheter (Robinson Model)
Medicine Products: